Phibro Animal Health CORP 10-Q quarterly reports

Phibro Animal Health Corporation announced a 10% increase in net sales for the third quarter of fiscal year 2026, driven by robust performance in its Animal Health segment.

Phibro Animal Health Corporation reported significantly increased net sales and net income for the quarter and six months ended December 31, 2025, driven by the Zoetis acquisition and organic growth.

Phibro Animal Health Corporation reported a 40% surge in net sales and a significant increase in net income for the quarter ended September 30, 2025, largely driven by its recent Zoetis acquisition and strong Animal Health segment growth.

Phibro Animal Health Corporation reports a significant increase in net sales and operating income for Q3 2025, primarily driven by the acquisition of Zoetis' medicated feed additive portfolio and overall sales growth.

Phibro Animal Health Corporation reports a significant increase in net sales and operating income for the second quarter of fiscal year 2025, primarily driven by the acquisition of Zoetis's medicated feed additive portfolio and increased demand across its segments.

Phibro Animal Health Corporation reported a significant increase in net income for the quarter ended September 30, 2024, driven by strong sales growth and improved gross margins.

Phibro Animal Health Corporation's Q3 2024 results show a slight increase in net sales but a decrease in net income, alongside a significant strategic acquisition.

Phibro Animal Health Corporation's latest quarterly report reveals a complex financial picture with increased sales in some segments offset by higher expenses and foreign currency losses.